Inflammation of the brain in Alzheimer's disease: Implications for therapy

Journal of Leukocyte Biology

Volumn 65, Issue 4, 1999, Pages 409-415

  McGeer, Patrick L ^a   McGeer, Edith G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Complement; Cytokines; Epidemiology; Immunology; Microglia

Indexed keywords

ALPHA INTERFERON; AMYLOID BETA PROTEIN; COLONY STIMULATING FACTOR; GAMMA INTERFERON; INTERLEUKIN DERIVATIVE; LYMPHOTOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL MODEL; BRAIN PROTECTION; CELL ACTIVATION; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; DRUG EFFICACY; ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; MICROGLIA; MOLECULAR DYNAMICS; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0032944604     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.65.4.409     Document Type: Review

References (50)

1. McGeer, P. L., Rogers, J. (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42, 447-449.
2. Lue, L. F., Brachova, L., Civin, W. H., Rogers, J. (1996) Inflammation, A beta deposition and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J. Neuropathol. Exp. Neurol. 55, 1083-1088.
3. McGeer, P. L., McGeer, E. G. (1995) The inflammatory system of brain: implications for therapy of Alzheimer and other neurodegenerative disorders. Brain Res. Rev. 21, 195-218.
4. Walker, D. G., McGeer, E. G., McGeer, P. L. (1997) Involvement of inflammation and complement in Alzheimer's disease. In: Clinical Neuroimmunology (J. Antel, G. Birnbaum, H. P. Hartung, eds.), Oxford, UK: Blackwell Scientific, 172-188.
5. Metchnikoff, E. (1892) Lecons sur la Pathologie Comparée de l'Inflammation, Paris: Masson.
6. van Furth, R. (1982) Current view on the mononuclear phagocyte system. Immunobiol. 161, 178-185.
7. Afagh, A., Cummings, B. J., Cribbs, D. H., Cotman, C. W., Tenner, A. J. (1996) Localization and cell association of Clq in Alzheimer's disease brain. Exp. Neurol. 138, 22-32.
8. Veerhuis, R., Janssen, I., Hack, C. E., Eikelenboom, P. (1996) Early complement components in Alzheimer's disease brains. Acta Neuropathol. 91, 53-60.
9. Webster, S., Lue, L. F., Brachova, L., Tenner, A. J., McGeer, P. L., Terai, K., Walker, D. G., Bradt, B., Cooper, N. R., Rogers, J. (1997) Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18, 415-421.
10. Terai, K., McGeer, E. G., McGeer, P. L. (1997) Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res. 769, 385-390.
11. Shen, Y., Li, R., McGeer, E. G., McGeer, P. L. (1997) Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 769, 391-395.
12. Schwab, C., Steele, J. C., McGeer, E. G., McGeer, P. L. (1997) Amyloid P immunoreactivity precedes C4d deposition on extracellular neurofibrillary tangles. Acta Neuropathol. 93, 87-91.
13. Duong, T., Nikolaeva, M., Acton, P. J. (1997) C-Reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Res. 749, 152-156.
14. Webster, S., Bradt, B., Rogers, J., Cooper, N. (1997) Aggregation state-dependent activation of classical complement pathway by the amyloid beta peptide. J. Neurochem. 69, 388-398.
15. Cribbs, D. H., Velazquez, P., Soreghan, B., Glabe, C. G., Tenner, A. J. (1997) Complement activation by cross-linked truncated and chimeric full-length beta-amyloid. Neurorep. 8, 3457-3462.
16. Emmerling, M. R., Spiegel, K., Watson, M. D. (1997) Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide. Immunopharmacol. 38, 101-109.
17. Webster, S., Rogers, J. (1996) Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J. Neurosci. Res. 46, 58-66.
18. McGeer, P. L., Walker, D. G., Pitas, R. E., Mahley, R. W., McGeer, E. G. (1997) Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta-amyloid protein activation of complement in vitro. Brain Res. 749, 135-138.
19. Webster, S., Bonnell, B., Rogers, J. (1997) Charge-based binding of complement component Clq to the Alzheimer amyloid beta-peptide. Am. J. Pathol. 150, 1531-1536.
20. Jiang, H., Robey, F. A., Gewurz, H. (1992) Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human Clq A chain. J. Biol. Chem. 267, 25587-25601.
21. Ying, S.-C., Gewurz, A. T., Jiang, H., Gewurz, H. (1993) Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of Clq. J. Immunol. 150, 169-176.
22. McGeer, E. G., McGeer, P. L. (1998) The future use of complement inhibitors for the treatment of neurological diseases. Drugs, 55, 739-746.
23. Fukumoto, H., Asami-Odaka, A., Suzuki, N., Iwasubo, T. (1996) Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. Neurodegeneration 5, 13-17.
24. DiPatre, P. L., Gelman, B. B. (1997) Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in hippocampus. J. Neuropathol. Exp. Neurol. 56, 143-149.
25. Taupenot, L., Ciesielski-Traska, J., Ulrich, G., Chasserot-Golaz, S., Aunis, D., Bader, M. F. (1996) Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neurosci. 72, 377-389.
26. Klegeris, A., Walker, D. G., McGeer, P. L. (1997) Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Res. 747, 114-121.
27. Giulian, D., Haverkamp, L. J., Yu, J. H., Karshin, W., Tom, D., Li, J., Kirkpatrick, J., Kuo, L. M., Roher, A. E. (1996) Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J. Neurosci. 16, 6021-6037.
28. Klegeris, A., McGeer, P. L. (1997) β-Amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J. Neurosci. Res. 49, 229-235.
29. Roher, A. E., Chaney, M. O., Kuo, Y. M., Webster, S. D., Stine, W. B., Haverkamp, L. J., Woods, A. S., Cotter, R. J., Tuohy, J. M., Krafft, G. A., Bonnell, B. S., Emmerling, M. R. (1996) Morphology and toxicity of A beta(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271, 20631-20635.
30. Barger, S. W., Harmon, A. D. (1997) Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388, 878-881.
31. Ma, J., Brewer, H. B. Jr., Potter, H. (1996) Alzheimer A beta neurotoxicity: promotion by antichymotrypsin. ApoE4; inhibition by A beta-related peptides. Neurobiol. Aging 17, 773-780.
32. Fagarasan, M. O., Aisen, P. S. (1996) IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity inPC 12 cells. Brain Res. 723, 231-234.
33. Dzenko, K. A., Weltzien, R. B., Pachter, J. S. (1997) Suppression of A beta-induced monocyte neurotoxicity by anti-inflammatory compounds. J. Neuroimmunol. 80, 6-12.
34. Klegeris, A., Walker, D. G., McGeer, P. L. (1997) Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J. Neuroimmunol. 78, 152-161.
35. McGeer, E. G , McGeer, P. L. (1997) Inflammatory cytokines in the CNS. CNS Drugs 7, 214-287.
36. Zhao, B., Schwartz, J. P. (1998) Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. J. Neurosci. Res. 52, 7-16.
37. Forloni, G., Mangiarotti, F., Angeretti, N., Lucca, E., De Simoni, M. G. (1997) Beta-amyloid fragment potentiates IL-6 and TNF-alpha secretion by LPS in astrocytes but not in microglia. Cytokine 9, 759-762.
38. Chong, Y. (1997) Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. Life Sci. 61, 2323-2333.
39. Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B., Saido, T. C., Hsiao, K., Cole, G. M. (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 152, 307-317.
40. Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K. H., Mistl, C., Rothacher, S., Ledermann, B., Burki, K., Frey, P., Paganetti, P. A., Waridel, C., Calhoun, M. E., Jucker, M., Probst, A., Staufenbiel, M., Sommer, B. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94, 13287-13292.
41. Heyser, C. J., Masliah, E., Samimi, A., Campbell, I. L., Gold, L. H. (1997) Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc. Natl. Acad. Sci. USA 94, 1500-1505.
42. Bellinger, F. P., Madamba, S. G., Campbell, I. L., Siggins, G. R. (1995) Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci. Lett. 198, 95-98.
43. Hausswegrzyniak, B., Dobrzanski, P., Snoehr, J. D., Wenk, G. L. (1998) Chronic neuroinflammation in rats reproduce components of the neurobiology of Alzheimer's disease. Brain Res. 780, 294-303.
44. Ma, T. C., Zhu, X. Z. (1997) Suppression of lipopolysaccharide-induced impairment of active avoidance and interferon-6-induced increase of prostaglandin E2 release in rats by indometacin. Arzn. Forsch. 47, 595-597.
45. McGeer, P. L., Schulzer, M., McGeer, E. G. (1996) Arthritis and anti-inflammatory agents as negative risk factors for Alzheimer disease: A review of seventeen epidemiological studies. Neurology 47, 425-432.
46. Breitner, J. C. S., Gau, B. A., Welsh, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., Anthony, J. C. (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology 44, 227-232.
47. Breitner, J. C. S., Welsh, K. A., Helms, M. J., Gaskell, P. C., Gau, B. A., Roses, A. D., Pericak-Vance, M. A., Saunders, A. M. (1995) Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16, 523-530.
48. Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., Brandt, J. (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51-55.
49. Doraiswamy, P. M., Krishen, A., Stallone, F., Martin, W. L., Potts, N. L. S., Metz, A. DeVeaugh-Geiss, J. (1996) NSAIDs and cognition in Alzheimer's disease. Neurology 46, 1994.
50. Rogers, J., Kirby, L. C., Hempelman, S. R. Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., Kogan, F. (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609-1611.